Related references
Note: Only part of the references are listed.Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study
Wendy B. London et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation
Sander Greenland et al.
CLINICAL TRIALS (2008)
Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over
F. M. -S. Barthel et al.
STATISTICS IN MEDICINE (2006)
Estimating treatment effects in randomized trials with treatment switching
IR White
STATISTICS IN MEDICINE (2006)
Statistical inference for cancer trials with treatment switching
J Shao et al.
STATISTICS IN MEDICINE (2005)
Calculation of sample size in survival trials: The impact of informative noncompliance
Q Jiang et al.
BIOMETRICS (2004)
Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: An application in a clinical trial of unresectable non-small-cell lung cancer
T Yamaguchi et al.
STATISTICS IN MEDICINE (2004)
Adjusting treatment comparisons to account for non-randomized interventions: an example from an angina trial
IR White et al.
STATISTICS IN MEDICINE (2003)
Sample size correction for treatment crossovers in randomized clinical trials with a survival endpoint
R Porcher et al.
CONTROLLED CLINICAL TRIALS (2002)
Estimating a treatment effect in survival studies in which patients switch treatment
M Branson et al.
STATISTICS IN MEDICINE (2002)
Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials
JK Lunceford et al.
BIOMETRICS (2002)
Statistical power for a long-term survival trial with a time-dependent treatment effect
JD Lu et al.
CONTROLLED CLINICAL TRIALS (2000)
Marginal structural models and causal inference in epidemiology
JM Robins et al.
EPIDEMIOLOGY (2000)
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men
MA Hernan et al.
EPIDEMIOLOGY (2000)
Share Paper
